clinically studied News
-
Clinical Studies
Through the years we have heard from many T-Stat users that they would like to collect their case data, review and present their findings. The transferring of data was limited to physically doing this on the T-Stat with a thumb drive. Now we have a new feature that is built into our remote access web application OnCall. If you want to collect your data you can easily request this in ...
-
New Clinical Study
Gelmetix is happy to announce a clinical study has been approved by the French Medical Authorities to investigate the benefit of the injection of the DXM gel to help alleviating pain from Chronic Lower Back pain patients. Pr Jean Charles Le Huec, from Bordeaux, France will drive the study as Principal Investigator. Information can be obtained at Polyclinique Bordeaux Nord in France. ...
-
Healx receives IND and Orphan Drug Designation for fragile X clinical trial
Healx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound HLX-0201 for Fragile X syndrome. The clinical study will attempt to find at least one novel and effective combination therapy for Fragile X syndrome - the world’s leading inherited cause of autism and learning difficulties which affects ...
By Healx Ltd.
-
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wells Fargo Healthcare Conference on Friday, September 9, 2022, at 10:25 a.m. ET / 7:25 a.m. PT in Boston. The presentation will be accessible ...
-
Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wedbush PacGrow Healthcare Conference’s panel discussion, “ADCs – Take Me to Your Tumor” on Wednesday, August 10, 2022, ...
-
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology ...
-
Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. Presentation Details: Credit Suisse 31st Annual Healthcare Conference Format: Presentation Date: Wednesday, ...
-
Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. Presentation Details: Piper Sandler 34th Annual Healthcare Conference Format: Fireside Chat Date: Wednesday, ...
-
Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in a Phase 1 study of an investigational candidate resulting from the collaboration between Sutro and Merck, known as MSD outside the United ...
-
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...
-
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...
-
4Q 2021 Stakeholder Update
Progress Update December 27th, 2021 Year End Summary 2021 was a great year of progress for Second Heart Assist, Inc. We completed a large series of large animals with long duration use at Texas Heart Institute with great success. We believe we are set now to begin a cardio-renal syndrome clinical study with 24 hours circulatory assist support time in 1Q 2022. Our team believes we are in the ...
-
Leonhardt’s Launchpads Accelerator to Showcase Eight Innovation Assets and Startups At 2022 Demo Day
Irvine, Calif., Nov. 16th, 2021 /PRDistribution/ — Leonhardt’s Launchpads announced today that they will showcase eight graduates of their innovation and startup launch accelerator program on a Demo Day. The event will occur both in person and virtually on Friday, January 14, 2022, at 3 pm PT at UCI Research Park, University Lab Partners, 5270 California Avenue, Suite 300, Irvine, CA ...
-
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy. The amendment increases the study duration for patients to 48 ...
-
Vektor Medical Initiates Clinical Study of vMap
Vektor Medical, Inc. announced the start of its clinical study to evaluate vMap™. Using patients who have previously undergone a clinically-indicated electrophysiology study and successful ablation, the purpose of this study is to clinically validate the use of vMap™ in providing arrhythmia/pacing hotspots for analysis by a physician. vMap™ has been designed as the next ...
-
Fractyl Health Announces the FDA’s Authorization of Expanding the Revitalize-1 Study’s Sample Size
LEXINGTON, Mass., November 30, 2021 – Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today the United States Food and Drug Administration’s (FDA’s) authorization to expand its Revitalize-1 pivotal clinical study (formerly known as REVITA-T2Di) sample size from 288 to 420. ...
-
Kardium announces $115M in new financing for innovative atrial fibrillation treatment
VANCOUVER, British Columbia – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $115 million in a new financing round. The round is led by Fidelity Management & Research Company LLC., together with follow-on participation by funds and accounts advised by T. Rowe Price Associates, Inc. The new financing will be ...
By Kardium Inc.
-
We are looking for a Clinical Project Manager
Join us when we are expanding our unit with another Clinical Project Manager. In this role, you will lead the planning, execution and documentation of clinical studies for our late clinical phase vaccine products. Join us in our work to give people worldwide a longer and better life. We are an entrepreneurial company and experts in global vaccine development, manufacturing, registration and ...
-
Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva® Advanced Cervical Scan, based on its patented biophotonic technology, announced today it had passed the regulatory compliance review at the Department of Obstetrics & Gynecology Hospital of Fudan University located in Shanghai. Clinical trials there and at three other centers are expected to begin this quarter. GTHP also ...
-
Canaquest - Recent developments
Pharmaceutical: We are perfecting our CQ-001 Drug Candidate (CBD based IP formula) delivery system for Epilepsy in readiness for another Clinical Study for efficacy at the Ontario Brain Institute “OBI”……targeting September. Our first Clinical Study at OBI already achieved a 20% reduction in seizures……..we believe we can do better with our more concentrated ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you